Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sage Therapeutics, Inc. - Common Stock (NQ: SAGE )

5.610 +0.610 (+12.20%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sage Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
The Analyst Verdict: Sage Therapeutics In The Eyes Of 13 Experts
Via Benzinga
Rivian Automotive Cuts Production Outlook, Joins EVgo And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sage Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Outset Medical, Starbucks, Endava, and Sage and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
SAGE THERAPEUTICS, INC. (NASDAQ: SAGE) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Sage Therapeutics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Methode Electronics, Starbucks, Endava, and Sage and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAGE
From The Rosen Law Firm PA
Via GlobeNewswire
Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate
Sage Therapeutics announced Biogen's decision to terminate their collaboration on SAGE-324 following negative results from a Phase 2 study, with Sage resuming full ownership of the asset by February... 
Via Benzinga
Sage Therapeutics Announces Discontinuation of the Collaboration with Biogen on the SAGE-324 Program
From Sage Therapeutics, Inc.
Via Business Wire
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sage Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
SAGE THERAPEUTICS, INC. (NASDAQ: SAGE) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Sage Therapeutics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sage, Outset Medical, Allarity, and Super Micro and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sage Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sage, Outset Medical, and Super Micro and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Sage Therapeutics, Inc. (SAGE)
From Glancy Prongay & Murray LLP
Via Business Wire
SAGE CLASS ACTION: Sage Therapeutics, Inc. Stockholders Should Contact Robbins LLP for Information About the Securities Class Action Lawsuit
From Robbins LLP
Via GlobeNewswire
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Sage Therapeutics, Inc. (SAGE)
From Law Offices of Howard G. Smith
Via Business Wire
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAGE
From The Rosen Law Firm PA
Via GlobeNewswire
SAGE THERAPEUTICS, INC. (NASDAQ: SAGE) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Sage Therapeutics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Starbucks, Sage, Outset Medical, and Super Micro and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Sage Therapeutics, Inc. (SAGE) Investors
From Glancy Prongay & Murray LLP
Via Business Wire
Faruqi & Faruqi Reminds Sage Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 - SAGE
From Faruqi & Faruqi LLP
Via GlobeNewswire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Sage Therapeutics, Inc. (SAGE) Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Sage Therapeutics, Inc. (SAGE) Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Sage Therapeutics, Inc. (SAGE) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Sage Therapeutics, Inc. (SAGE) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
SAGE SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Starbucks, Sage, Outset Medical, and Super Micro and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Shareholder Rights Attorneys Robbins LLP Reminds SAGE Stockholders of the Opportunity to Lead the Sage Therapeutics, Inc. Class Action
From Robbins LLP
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.